- Home
- AYTU vs ZSTK Comparison
AYTU vs ZSTK Comparison
Compare AYTU & ZSTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AYTU | ZSTK |
|---|---|---|
| Founded | N/A | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.7M | 27.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | AYTU | ZSTK |
|---|---|---|
| Price | $2.27 | $9.10 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $9.33 | N/A |
| AVG Volume (30 Days) | 88.9K | ★ 223.8K |
| Earning Date | 02-03-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $62,640,000.00 | $57,609,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $47.32 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 2.00 | ★ 24.71 |
| 52 Week Low | $0.95 | $5.86 |
| 52 Week High | $3.07 | $47.00 |
Technical Indicators
Market Signals| Indicator | AYTU | ZSTK |
|---|---|---|
| Relative Strength Index (RSI) | 39.79 | 64.08 |
| Support Level | $2.28 | $7.51 |
| Resistance Level | $2.50 | $10.42 |
| Average True Range (ATR) | 0.15 | 1.55 |
| MACD | -0.05 | 0.20 |
| Stochastic Oscillator | 21.05 | 42.41 |
Price Performance
Historical ComparisonAbout AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.